Clinical Trials Logo
  1. Home
  2. Lymphoma, Large-Cell, Diffuse
  3. NCT00561379

Diffuse Large B Cell Lymphoma of the Adult: Randomization Between High Dose Chemotherapy With Rituximab and CHOP 14-Rituximab

Lymphoma, Large-Cell, Diffuse Clinical Trial

Official title:
Frontline Therapy of Diffuse Large B Cell Lymphoma of the Adult ( 18 to 60 Years Old): Randomization Between High Dose Chemotherapy With Rituximab and CHOP 14 -Rituximab. Multicentric Randomized Prospective Trial.

Clinical Trial Summary

The aim of the protocol is to compare the outcome of patients with DLBCL stage II bulky, III or IV with 1 to 3 adverse prognostic factors according to the International prognostic index. Patients with eligibility criteria and who gave informed consent will be randomised between CHOP-14- Rituximab x 8 courses and High dose chemotherapy with rituximab including autologous stem cell support. The aim of the study is to compare the Event free survival between the two arms and to gain insight into the prognostic significance of several biological markers gathered at the time of diagnosis/randomisation ( i.e. Fcgamma R III A genotyping, DNA profile and BCL é expression).

Clinical Trial Description

Diffuse Large B Cell Lymphoma not previously treated ;

Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT00561379
Study type Interventional
Source Nantes University Hospital
Contact
Status Completed
Phase N/A
Start date April 2005
Completion date May 2013
View Details
See also
  Status Clinical Trial Phase
Completed NCT00379574 - Bortezomib Plus CHOP Every 2 Weeks for Advanced Stage DLBCL Phase 1/Phase 2
Terminated NCT00514722 - Pilot Study of Umbilical Cord Blood Transplantation in Adult Patient With Advanced Hematopoietic Malignancies N/A
Completed NCT00169130 - ACVBP Followed by ASCT in Patients With BCL-2 Positive Diffuse Large B-Cell Lymphoma Phase 2/Phase 3
Terminated NCT00135499 - R-ACVBP Versus R-CHOP in Patients Aged 60-65 With Diffuse Large B-cell Lymphoma Phase 3
Terminated NCT00511043 - PTK787 in Refractory or Relapsed Diffuse Large Cell Lymphoma Phase 2
Completed NCT00823719 - Phase II Study of Ofatumumab Plus Ifosfamide, Carboplatin, Etoposide (ICE) or Dexamethasone, Cytarabine, Cisplatin (DHAP) Chemotherapy Regimen in Relapsed/ Refractory Diffuse Large B Cell Lymphoma (DLBCL) Phase 2
Completed NCT01014208 - Ofatumumab Versus Rituximab Salvage Chemoimmunotherapy Followed by Autologous Stem Cell Transplant in Relapsed or Refractory Diffuse Large B Cell Lymphoma Phase 3
Completed NCT00001237 - Pilot Protocol for the Treatment of Patients With Small Non-Cleaved and Diffuse Large Cell Lymphomas Phase 2
Terminated NCT00498914 - Study of YM155 in Refractory Diffuse Large B-cell Lymphoma (DLBCL) Subjects Phase 2
Completed NCT00137995 - R-ICE Versus R-DHAP in Patients Aged 18-65 With Relapse Diffuse Large B-cell Lymphoma Phase 3
Completed NCT00498043 - A Study of Two Associations of Rituximab and Chemotherapy, With a PET-driven Strategy, in Lymphoma Phase 2
Completed NCT00622388 - Ofatumumab in Patients With Relapsed/Progressive Diffused Large B-Cell Lymphoma (DLBCL) Ineligible for or Relapse/Progression After Transplant Phase 2